SLC5A2 and cardiovascular disorder: For example, in patients with diabetes mellitus, which constituted more than half of this study’s cohort, novel antihyperglycemic agents such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) agonists have been shown to significantly reduce different MACCE in patients with established cardiovascular disease [31].